{"id":"W4389241247","doi":"10.1007/s00277-023-05552-4","title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Pharma; Sierra Oncology; Taiho Pharmaceutical; Incyte; CTI Biopharma; MorphoSys; Celgene; Astex Pharmaceuticals; Servier; Pfizer; Constellation Pharmaceuticals; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Hypomethylating agent; Oncology; Pembrolizumab; Myeloid leukemia; Lenalidomide; Decitabine; Cancer; Bone marrow; Multiple myeloma; Immunotherapy; DNA methylation","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001383872,0.00146235,0.002369572,0.000408673,0.0005291278,0.001250345,0.0008735499,0.001068583,0.00411879],"category_scores_gemma":[0.0008349861,0.0005958427,0.001665285,0.0005026234,0.0009883289,0.001241428,0.0003633338,0.004081515,0.0009565495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162107,"about_ca_system_score_gemma":0.001587082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001363567,"about_ca_topic_score_gemma":0.004038927,"domain_scores_codex":[0.9996271,0.0001699841,0.0000187396,0.00006917415,0.00002542259,0.00008961793],"domain_scores_gemma":[0.9994583,0.00008260267,0.00007594243,0.00003862386,0.00002741797,0.0003172236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8711222,0.02928336,0.003077966,0.0005134821,0.002028916,0.0001622378,0.0001793461,0.002253179,0.01992618,0.0003878862,0.004300551,0.06676468],"study_design_scores_gemma":[0.8012963,0.1865216,0.00605971,0.00003056794,0.0006748678,0.0001595678,0.00007162948,0.001190855,0.001525354,0.0002131252,0.002232543,0.00002390284],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911623,0.002667561,0.0004488407,0.001075238,0.0003062527,0.001178319,0.0008926407,0.0000845696,0.002184303],"genre_scores_gemma":[0.9884146,0.00243582,0.001556154,0.001040102,0.000256397,0.001481232,0.002274011,0.00003243191,0.002509224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411879,"threshold_uncertainty_score":0.01377875,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112445603740638,"score_gpt":0.3582295439260402,"score_spread":0.3171050878886338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}